Enzo Biochem, Inc. (ENZ)
ENZ Stock Price Chart
Key Info
| Market Cap | 104.41M |
| Revenue (ttm) | 76.02M |
| Net Income (ttm) | -28.52M |
| Shares Out | 47.70M |
| EPS (ttm) | -0.60 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | December 3 |
| Last Price | $2.18 |
| Previous Close | $2.17 |
| Change ($) | 0.01 |
| Change (%) | 0.46% |
| Day's Open | 2.14 |
| Day's Range | 2.12 - 2.25 |
| Day's Volume | 210,547 |
| 52-Week Range | 1.82 - 3.87 |
ENZ Stock News
NEW YORK, NY, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or “The Company”), a leading biosciences and diagnostics company, announced today that Ian B. Walters, MD,...
NEW YORK, NY, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or “the Company”), a leading biosciences and diagnostics company, announced today that Mary Tagliaferri, M...
Direct-to-Consumer service will initially offer access to COVID-19 molecular and antibody testing and will expand to include other testing in the future
Enzo Biochem, Inc.'s (ENZ) on Q4 2020 Results - Earnings Call Transcript
Conference call and live webcast scheduled for today, Tuesday, October 13, 2020 at 4:30 pm (ET)
Conference Call and Webcast Scheduled for October 13, 2020, 4:30 pm ET
Enzo Biochem, Inc: Wildly Undervalued COVID-19 Test Play With Near-Term Catalysts
New initiative introduces Enzo’s Independent Pharmacy Testing Program with full range of products and services to support rapid and accurate testing to more residents of New York State New ini...
Shares of Enzo Biochem Inc. ENZ, +6.71% rallied 7.7% in premarket trading on Monday after the company said it received an emergency use authorization from the Food and Drug Administration for ...
Authorization Enables Clinical Labs to Purchase and Use Enzo’s AMPIPROBE® SARS-Cov-2 Test System without Further Validation Authorization Enables Clinical Labs to Purchase and Use Enzo’s AMPIP...
First Collaboration under Enzo’s School and Institution Testing (“SIT”) Program
Continues to Explore Opportunities for Use of the Compound as a Potential Treatment for COVID-19
Enzo Biochem, Inc. (ENZ) Q3 2020 Results - Earnings Call Transcript
NEW YORK, June 08, 2020 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, today reported results for the third quarter ended April 30, 2020.
Second Product Offering to Expand Disease Management within Enzo’s Comprehensive COVID-19 Program
NEW YORK, NY, April 29, 2020 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ), a leading biosciences and diagnostics company, today announced the recent issuance of U.S. Patent No. 10,624...
Enzo Biochem, Inc. (NYSE: ENZ) shares were rallying Thursday following an update from the company on its comprehensive COVID-19 program.
The COVID-19 outbreak has proved to be a catalyst for biotechs. Some issues that were wallowing in penny stock territory have posted stratospheric gains in the wake of efforts to develop diagn...
Enzo Biochem, Inc. (ENZ) Q1 2020 Results - Earnings Call Transcript
Enzo Biochem, Inc. (ENZ) Management on Q1 2020 Results - Earnings Call Transcript
Enzo Biochem, Inc. (ENZ) Q4 2019 Results - Earnings Call Transcript
Enzo Biochem, Inc. (ENZ) Q3 2019 Results - Earnings Call Transcript
Enzo Biochem, Inc. (ENZ) President Barry Weiner on Q3 2019 Results - Earnings Call Transcript
About ENZ
Enzo Biochem, an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Products, Clinical Services, and Therapeutics. The Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and... [Read more...]
| Industry Diagnostics & Research | Founded 1976 |
| CEO Elazar Rabbani | Employees 408 |
| Stock Exchange NYSE | Ticker Symbol ENZ |
Analyst Forecasts
The average 12-month stock price forecast for Enzo Biochem is 5.50, which is an increase of 152.29% from the latest price.